Literature DB >> 25267489

In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.

Evangelia Papadavid1, Penelope Korkolopoulou, Georgia Levidou, Angelica A Saetta, Theodora Papadaki, Marina Siakantaris, Vassiliki Nikolaou, Afroditi Oikonomidi, Ilenia Chatziandreou, Leonidas Marinos, Aggeliki Kolialexi, Alexandros Stratigos, Dimitrios Rigopoulos, Amanta Psyrri, Eftratios Patsouris, Christina Antoniou.   

Abstract

Deregulated signalling through phosphatidylinositol 3-kinase (PI3K) pathway plays a critical role in tumour initiation and progression. We have already shown that AKT is activated in skin lesions in Mycosis Fungoides (MF) and we herein further investigate the frequency and clinical significance of PTEN and PI3K at the protein and at the DNA level as well as the presence of AKT1 mutations in skin lesions from 50 patients with MF clinical stages I-IV in relation to clinicopathological features. Increased p-AKT expression correlated with poor prognosis in plaques (P = 0.0198), whereas p-AKT was an independent predictor of poor survival in the entire cohort (P = 0.017, HR = 1.012). PTEN cytoplasmic expression was found low or absent in all 77.3% of cases and inversely correlated with advanced clinical stages (P = 0.0744). Molecular analysis showed no AKT1 mutation, no PI3KCA copy number gain, only 1 case with PI3KCA mutation in exon 9 and 3 cases with PTEN mutations (7%) in exons 7, 8 and 5. The latter correlated with disease (P = 0.0253) and progression (P < 0.0001) free survival in tumour stage. Although activation of PI3K/AKT signalling pathway due to PTEN alterations is rarely attributed to abnormalities in PTEN, PI3K, and AKT1 genes, PTEN mutations exert a negative effect on patients' prognosis with tumours.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PI3K; PTEN; immunohistochemistry; molecular analysis; mycosis fungoides

Mesh:

Substances:

Year:  2014        PMID: 25267489     DOI: 10.1111/exd.12547

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

1.  Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.

Authors:  Aggeliki Tserga; Ilenia Chatziandreou; Nicolaos V Michalopoulos; Efstratios Patsouris; Angelica A Saetta
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

Review 2.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

3.  Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families.

Authors:  Janice P Dutcher; Peter H Wiernik; Leticia Varella; Rangaswamy Chintapatla
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

4.  Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Vassiliki Mpakou; Aris Spathis; Periklis G Foukas; Maria Dalamaga; Vasiliki Pappa; Evangelia Papadavid
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

5.  Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer.

Authors:  Dimitrios S Kanakoglou; Andromachi Pampalou; Dimitrios M Vrachnos; Eleni A Karatrasoglou; Dionysia N Zouki; Emmanouil Dimonitsas; Alexia Klonou; Georgia Kokla; Varvara Theologi; Errieta Christofidou; Stratigoula Sakellariou; Eleftheria Lakiotaki; Christina Piperi; Penelope Korkolopoulou
Journal:  Int J Oncol       Date:  2022-02-16       Impact factor: 5.650

6.  Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Berta Casar; Dalia de la Fuente-Vivas; Rocío García-Gómez; Kyriaki Lampadaki; Vasiliki Pappa; Evangelia Papadavid
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

7.  Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.

Authors:  Selinde S Wind; Manon A A Jansen; Melanie Rijsbergen; Michiel J van Esdonk; Dimitrios Ziagkos; Wing C Cheng; Tessa Niemeyer-van der Kolk; John Korsten; Agnieszka Gruszka; Debora Schmitz-Rohmer; David Bonnel; Raphael Legouffe; Florian Barré; Marcel W Bekkenk; Ellen R M de Haas; Koen D Quint; Melanie Rolli; Henk Johan Streefkerk; Jacobus Burggraaf; Maarten H Vermeer; Robert Rissmann
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.